New promising drug targets in cancer- and metastasis-initiating cells

Drug Discov Today. 2010 May;15(9-10):354-64. doi: 10.1016/j.drudis.2010.03.009. Epub 2010 Mar 23.


The unique properties of cancer- and metastasis-initiating cells endowed with a high self-renewal and aberrant differentiation potential (including their elevated expression levels of anti-apoptotic factors, multidrug transporters, and DNA repair and detoxifying enzymes) might be associated with their resistance to current clinical cancer therapies and disease recurrence. The eradication of cancer- and metastasis-initiating cells by molecular targeting of distinct deregulated signaling elements that might contribute to their sustained growth, survival, and treatment resistance, therefore, is of immense therapeutic interest. These novel targeted approaches should improve the efficacy of current therapeutic treatments against highly aggressive, metastatic, recurrent, and lethal cancers.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / pharmacology*
  • Drug Delivery Systems / methods*
  • Drug Resistance, Neoplasm
  • Drug Screening Assays, Antitumor / methods
  • Drugs, Investigational / administration & dosage*
  • Drugs, Investigational / pharmacology*
  • Humans
  • Models, Biological
  • Neoplasm Metastasis / prevention & control*
  • Signal Transduction / drug effects


  • Antineoplastic Agents
  • Drugs, Investigational